Phase 1, First-in-human, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, of ORKA-001 in Healthy Participants
Latest Information Update: 26 May 2025
At a glance
- Drugs ORKA 001 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; First in man
- Sponsors Oruka Therapeutics
Most Recent Events
- 20 May 2025 According to Oruka Therapeutics media release, company expects to share interim data from this trial, by year end (YE) 2025.
- 18 May 2025 Status changed from recruiting to active, no longer recruiting.
- 14 May 2025 According to Oruka Therapeutics media release, Company expects to share interim data from this trial, including initial PK data, in 3Q 2025